Biogen (BIIB) EPS (Basic) (2009 - 2026)

Biogen (BIIB) has reported EPS (Basic) for 18 consecutive years, with $2.17 the latest figure, recorded in Q1 2026.

• In Q1 2026, EPS (Basic) rose 31.86% year-over-year to $2.17; the TTM figure through Mar 2026 stood at $9.32 (down 7.95% YoY), while the FY2025 annual figure was $8.83, down 21.27% from the prior year.
• EPS (Basic) came in at $2.17 for Q1 2026 at Biogen, up from -$0.33 in the prior quarter.
• The five-year high for EPS (Basic) was $7.92 in Q3 2022, with the low at -$0.44 in Q3 2023.
• Average EPS (Basic) over 5 years is $3.01, with a median of $2.71 recorded in 2024.
• Across the five-year window, EPS (Basic) soared 969.52% in 2022 and sank 118.22% in 2025, its largest moves.
• Year by year, EPS (Basic) stood at $3.85 in 2022, then plunged by 55.29% to $1.72 in 2023, then advanced by 6.49% to $1.83 in 2024, then tumbled by 118.22% to -$0.33 in 2025, then jumped by 750.27% to $2.17 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $2.17, -$0.33, and $3.18 for Q1 2026, Q4 2025, and Q3 2025 respectively.